Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 15 |
| Active Pipeline (Recruiting Now) | 5 (5) |
| Completed vs Stopped Early | 3 / 7 (46.7%) |
| Median Closed Actual Enrollment | 50 participants |
| Physical Hospital Site Disclosure | 99.8% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Ohio State University Comprehensive Cancer Center | Columbus, OH | 4 |
| Columbia University Irving Medical Center | New York, NY | 4 |
| Vanderbilt University Medical Center | Nashville, TN | 3 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT03969420 | Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy | Phase II | TERMINATED |
| NCT05227209 | A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Assoc | Phase III | TERMINATED |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Sumitomo Pharma America across sibling Meru public-data platforms.
Explore interactive annual charts and M&A subsidiary rollups in the Sumitomo Pharma America Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.